— Know what they know.
Not Investment Advice

LBRX NASDAQ

LB Pharmaceuticals Inc Common Stock
1W: -3.3% 1M: +4.6% 3M: +1.6% YTD: +93.9% 1Y: +148.2%
$39.64
+0.30 (+0.76%)
After Hours: $43.55 (+3.91, +9.85%)
Weekly Expected Move ±8.8%
$32 $35 $39 $42 $46
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 62 · $1.3B mcap · 24M float · 1.56% daily turnover · Short 72% of daily vol
Credit Risk of going bust: lower than 80% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), LB Pharmaceuticals Inc Common Stock would be worth roughly what it owes.
Total debt $5.2M against a stock market value of $1.27B.
Distance to default 9.69 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.6M (short-term plus half of long-term), stock volatility 62.4%; Altman Z'' 14.47. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$0M
Revenue
+0.0% YoY
$-86M
Net Income
+0.0% YoY
$-83M
Free Cash Flow
+0.0% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

⚠️ Cash Burn Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE-25.8%
ROA-23.7%
ROIC-768.9%

Valuation

P/E-13.4
P/B3.6
EV/EBITDA-7.5

Leverage

Debt/Equity0.02
Current Ratio15.08
Interest Cov.0.0x

Quality Scores

Piotroski F2/9
Altman Z19.53
Beneish M0.00

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms